Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sana Biotechnology, Inc. - Common Stock (NQ:SANA)

4.690 +0.110 (+2.40%)
Streaming Delayed Price Updated: 3:24 PM EST, Jan 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sana Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash. 
Via Benzinga
News headline image
Sana Biotechnology Announces Preclinical Data Published in Nature Biotechnology Demonstrating its Hypoimmune-Engineered Cells Escape Immune Detection and Survive While Remaining Fully Functional
From Sana Biotechnology, Inc
Via GlobeNewswire
Morgan Stanley Maintains Overweight Rating for Sana Biotechnology: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Sana Biotechnology Outlines Pipeline Prioritization, Reduces Workforce ↗
 
Via Benzinga
News headline image
Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
7 High-Potential Penny Stocks in the Biotech Sector ↗
Most of the biggest biotech stocks on the market started off as unknown penny stocks. Here are seven hot ones to consider. 
Via InvestorPlace
News headline image
Sana Biotechnology to Present at May 2023 Investor Conferences
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology Announces the Acceptance of Six Abstracts for Presentation at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2023 ↗
 
Via Benzinga
News headline image
Sana Biotechnology to Host Research & Development Day
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
The Top 3 Biotech Stocks to Watch in 2023 ↗
Investors would be wise to keep an eye on the biotech boom, and these top biotech stocks to watch as we get deeper into 2023. 
Via InvestorPlace
News headline image
Sana Biotechnology Highlights Preclinical Hypoimmune Data for its Allogeneic CAR T Platform and Advancements with its In Vivo Fusogen Platform with Four Presentations at the 2023 AACR Annual Meeting
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
2 Growth Stocks That Jumped 42% and 58% Last Week: Can They Still Climb Higher? ↗
Good news drove shares of these stocks through the roof last week, but investors should be more concerned about their paths forward. 
Via The Motley Fool
News headline image
Why Shares of Sana Biotechnology Jumped This Week ↗
The company announced details of research on two of its pre-clinical therapies. 
Via The Motley Fool
News headline image
Why Sana Biotechnology Shares Are Trading Higher Today ↗
Sana Biotechnology (NASDAQ: SANA) shares are trading higher after the company announced the publication of a paper in Nature Communications on hypoimmune-modified allogeneic CD19-directed CAR T cells. 
Via Benzinga
News headline image
Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Why ViewRay Shares Are Trading Lower By 32%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers CXApp Inc. (NASDAQ: CXAI) jumped 105% to $3.28 after climbing over 20% on Wednesday. 
Via Benzinga
News headline image
Sana Biotechnology Announces Preclinical Data Published in Nature Communications Demonstrating the Ability of its Hypoimmune Allogeneic CD19-directed CAR T Cells to Evade Immune Rejection and Produce Durable Anti-Tumor Responses
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology Announces Preclinical Data Published in Science Translational Medicine Showing its Hypoimmune Pancreatic Islet Cells Evaded Allogeneic and Autoimmune Rejection and Controlled Type 1 Diabetes in Preclinical Model
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology Announces the Appointment of Two Pioneers in Drug Discovery and Development to Lead its R&D Organization
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology Announces the Acceptance of Four Abstracts for Presentation at the 2023 American Association for Cancer Research Annual Meeting
Late-breaking poster presentation to highlight preclinical data demonstrating that the increased potency of CD8-targeted fusosomes enhances CAR gene delivery to resting primary T cells 
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology to Present at the Cowen 43rd Annual Health Care Conference
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology to Present at the Guggenheim Healthcare Talks 5th Annual Oncology Conference
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  On Wednesday, 258 companies hit new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  On Monday, 297 companies reached new 52-week lows. 
Via Benzinga
News headline image
Sana Biotechnology Highlights Hypoimmune Allogeneic CAR T Cell Programs and in vivo Technology Platform with Six Presentations at 2022 ASH Annual Meeting
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology Confirms Key Program Timelines and Announces Portfolio Prioritization
From Sana Biotechnology, Inc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.